Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | Euronext Growth Oslo |
Sektor | Hälsovård |
Industri | Medicinteknik |
2021-04-09 08:00:00
The National Committee of Health Research Ethics (NVK) in Denmark has approved
the "SBE-01 study", a first-in-human, phase I clinical trial in patients with
chronic wounds. The study has now received full regulatory clearance to make the
final preparations for initiation. Reference is made to the previous stock
announcement of 15th March 2021 regarding authorisation from the Danish
Medicines Agency.
"This rapid approval by the relevant regulatory bodies in Denmark will enable us
to start the study during Q2-2021" says Glenn Gundersen, Medical Director in
SoftOx Solutions.
SBE-01: EudraCT no. 2021-000314-42.
For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, Medical Director of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599
About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth
Oslo. Our Vison is "Helping the world fighting infections - developing new ways
of eradicating infections and fighting antimicrobial resistance". We are working
to combat major threats to human health, namely the emergence of antimicrobial
resistance (AMR), biofilm infections in chronic wounds and the spread of
viruses. For more information on SoftOx, visit www.soft-ox.com